{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:47:09Z","timestamp":1789948029106,"version":"4.0.1"},"reference-count":131,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.neuropharm.2013.10.025","type":"journal-article","created":{"date-parts":[[2013,10,31]],"date-time":"2013-10-31T21:46:42Z","timestamp":1383256002000},"page":"103-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["What's wrong with epigenetics in Huntington's disease?"],"prefix":"10.1016","volume":"80","author":[{"given":"Luis M.","family":"Valor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deisy","family":"Guiretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2013.10.025_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1756-8935-3-18","article-title":"Lessons from genome-wide studies: an integrated definition of the coactivator function of histone acetyl transferases","volume":"3","author":"Anamika","year":"2010","journal-title":"Epigenetics Chromatin"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1006\/nbdi.2002.0562","article-title":"Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression","volume":"11","author":"Andreassen","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib3","doi-asserted-by":"crossref","first-page":"11833","DOI":"10.1523\/JNEUROSCI.5831-12.2013","article-title":"Disassociation of histone deacetylase-3 from normal huntingtin underlies mutant huntingtin neurotoxicity","volume":"33","author":"Bardai","year":"2013","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib5","series-title":"Huntington's Disease","year":"2004"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib4","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1523\/JNEUROSCI.3344-05.2006","article-title":"Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity","volume":"26","author":"Bates","year":"2006","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.18632\/aging.100453","article-title":"Is histone acetylation the most important physiological function for CBP and p300?","volume":"4","author":"Bedford","year":"2012","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib8","doi-asserted-by":"crossref","first-page":"10720","DOI":"10.1523\/JNEUROSCI.2126-08.2008","article-title":"Huntingtin modulates transcription, occupies gene promoters in\u00a0vivo, and binds directly to DNA in a polyglutamine-dependent manner","volume":"28","author":"Benn","year":"2008","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib7","doi-asserted-by":"crossref","first-page":"e5747","DOI":"10.1371\/journal.pone.0005747","article-title":"Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6\/2 mouse model of Huntington's disease","volume":"4","author":"Benn","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib9","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1111\/j.1582-4934.2008.00543.x","article-title":"The polyubiquitin Ubc gene modulates histone H2A monoubiquitylation in the R6\/2 mouse model of Huntington's disease","volume":"13","author":"Bett","year":"2009","journal-title":"J.\u00a0Cell. Mol. Med."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib11","doi-asserted-by":"crossref","first-page":"e20696","DOI":"10.1371\/journal.pone.0020696","article-title":"Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6\/2 mouse model of Huntington's disease","volume":"6","author":"Bobrowska","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib10","doi-asserted-by":"crossref","first-page":"e34805","DOI":"10.1371\/journal.pone.0034805","article-title":"SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in\u00a0vivo","volume":"7","author":"Bobrowska","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000330505","article-title":"Pcaf modulates polyglutamine pathology in a Drosophila model of Huntington's disease","volume":"9","author":"Bodai","year":"2012","journal-title":"Neurodegener Dis."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib13","doi-asserted-by":"crossref","first-page":"10719","DOI":"10.1093\/nar\/gks865","article-title":"Histone H2A variants in nucleosomes and chromatin: more or less stable?","volume":"40","author":"Bonisch","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib14","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/hmg\/8.9.1647","article-title":"Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin","volume":"8","author":"Boutell","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib15","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/embor.2012.78","article-title":"Shaping the landscape: mechanistic consequences of ubiquitin modification of chromatin","volume":"13","author":"Braun","year":"2012","journal-title":"EMBO Rep."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fonc.2012.00026","article-title":"Histone ubiquitination and deubiquitination in transcription, DNA damage response, and cancer","volume":"2","author":"Cao","year":"2012","journal-title":"Front. Oncol."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib17","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/nrn1806","article-title":"Normal huntingtin function: an alternative approach to Huntington's disease","volume":"6","author":"Cattaneo","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib18","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.mcn.2005.05.003","article-title":"Mutant huntingtin represses CBP, but not p300, by binding and protein degradation","volume":"30","author":"Cong","year":"2005","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib19","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1242\/jcs.00804","article-title":"Chromatin remodeling and neuronal response: multiple signaling pathways induce specific histone H3 modifications and early gene expression in hippocampal neurons","volume":"116","author":"Crosio","year":"2003","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.pneurobio.2007.03.004","article-title":"Transcriptional signatures in Huntington's disease","volume":"83","author":"Cha","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.nbd.2005.11.001","article-title":"Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease","volume":"22","author":"Chen-Plotkin","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib22","doi-asserted-by":"crossref","first-page":"13066","DOI":"10.1523\/JNEUROSCI.2378-10.2010","article-title":"CREB binding protein is required for both short-term and long-term memory formation","volume":"30","author":"Chen","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib23","article-title":"Effects of the pimelic diphenylamide histone deacetylase inhibitor HDACi 4b on the R6\/2 and N171-82Q mouse models of Huntington's disease","volume":"5","author":"Chen","year":"2013","journal-title":"PLoS Curr."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib24","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1038\/npp.2011.128","article-title":"Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease","volume":"36","author":"Chiu","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.mcn.2011.11.003","article-title":"Suppression of aggregate formation of mutant huntingtin potentiates CREB-binding protein sequestration and apoptotic cell death","volume":"49","author":"Choi","year":"2012","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib26","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1126\/science.1175371","article-title":"Lysine acetylation targets protein complexes and co-regulates major cellular functions","volume":"325","author":"Choudhary","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib27","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.neuron.2011.05.019","article-title":"Epigenetic mechanisms in cognition","volume":"70","author":"Day","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/npp.2011.85","article-title":"Epigenetic treatments for cognitive impairments","volume":"37","author":"Day","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib29","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1101\/gad.2037511","article-title":"CpG islands and the regulation of transcription","volume":"25","author":"Deaton","year":"2011","journal-title":"Genes Dev."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib30","doi-asserted-by":"crossref","first-page":"e1001257","DOI":"10.1371\/journal.pbio.1001257","article-title":"Histone deacetylase complexes promote trinucleotide repeat expansions","volume":"10","author":"Debacker","year":"2012","journal-title":"PLoS Biol."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib31","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1523\/JNEUROSCI.0037-07.2007","article-title":"Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation","volume":"27","author":"Dompierre","year":"2007","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib32","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1126\/science.1072613","article-title":"Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease","volume":"296","author":"Dunah","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib33","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nsmb.2070","article-title":"Combinatorial readout of histone H3 modifications specifies localization of ATRX to heterochromatin","volume":"18","author":"Eustermann","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib34","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","article-title":"Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice","volume":"23","author":"Ferrante","year":"2003","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib35","doi-asserted-by":"crossref","first-page":"10335","DOI":"10.1523\/JNEUROSCI.2599-04.2004","article-title":"Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease","volume":"24","author":"Ferrante","year":"2004","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib36","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1074\/jbc.M410210200","article-title":"Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease","volume":"280","author":"Gardian","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib37","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/j.1460-9568.2009.06649.x","article-title":"Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6\/2 mouse model of Huntington's disease","volume":"29","author":"Giampa","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib38","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.1074\/jbc.M708192200","article-title":"Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment","volume":"283","author":"Giorgini","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib39","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/hmg\/ddr552","article-title":"Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity","volume":"21","author":"Giralt","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib40","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1093\/hmg\/ddg242","article-title":"DNA damage induced by polyglutamine-expanded proteins","volume":"12","author":"Giuliano","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib41","doi-asserted-by":"crossref","first-page":"e15367","DOI":"10.1371\/journal.pone.0015367","article-title":"Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates","volume":"5","author":"Globisch","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib42","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1093\/hmg\/ddh317","article-title":"Genome-wide demethylation destabilizes CTG.CAG trinucleotide repeats in mammalian cells","volume":"13","author":"Gorbunova","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib43","doi-asserted-by":"crossref","first-page":"e1003051","DOI":"10.1371\/journal.pgen.1003051","article-title":"Transcription elongation and tissue-specific somatic CAG instability","volume":"8","author":"Goula","year":"2012","journal-title":"PLoS Genet."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib44","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/npp.2012.125","article-title":"The dynamics of DNA methylation in schizophrenia and related psychiatric disorders","volume":"38","author":"Grayson","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/B978-0-12-416027-9.00002-4","article-title":"Functions of DNA methylation and hydroxymethylation in mammalian development","volume":"104","author":"Guibert","year":"2013","journal-title":"Curr. Top. Dev. Biol."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib46","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/nn.2900","article-title":"Neuronal activity modifies the DNA methylation landscape in the adult brain","volume":"14","author":"Guo","year":"2011","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib47","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cell.2011.03.022","article-title":"Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain","volume":"145","author":"Guo","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib48","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.tig.2011.06.006","article-title":"Histone modification: cause or cog?","volume":"27","author":"Henikoff","year":"2011","journal-title":"Trends Genet."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib49","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib50","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1002\/mds.21632","article-title":"Sodium phenylbutyrate in Huntington's disease: a dose-finding study","volume":"22","author":"Hogarth","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib51","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1471-4159.2003.01991.x","article-title":"Histone deacetylase activity is retained in primary neurons expressing mutant huntingtin protein","volume":"87","author":"Hoshino","year":"2003","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib52","doi-asserted-by":"crossref","first-page":"e8888","DOI":"10.1371\/journal.pone.0008888","article-title":"The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing","volume":"5","author":"Huang","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib53","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00001756-200303240-00007","article-title":"Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation","volume":"14","author":"Igarashi","year":"2003","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib54","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/jnr.21881","article-title":"DNA breakage and induction of DNA damage response proteins precede the appearance of visible mutant huntingtin aggregates","volume":"87","author":"Illuzzi","year":"2009","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib55","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nsmb.2062","article-title":"ATRX ADD domain links an atypical histone methylation recognition mechanism to human mental-retardation syndrome","volume":"18","author":"Iwase","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib56","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/nm.2828","article-title":"Epigenetic mechanisms in neurological disease","volume":"18","author":"Jakovcevski","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib57","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12035-012-8274-9","article-title":"Deregulation of BRCA1 leads to impaired spatiotemporal dynamics of gamma-H2AX and DNA damage responses in Huntington's disease","volume":"45","author":"Jeon","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib58","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cell.2009.03.018","article-title":"Acetylation targets mutant huntingtin to autophagosomes for degradation","volume":"137","author":"Jeong","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib59","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1093\/hmg\/dds379","article-title":"Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems","volume":"21","author":"Jia","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib60","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.nbd.2012.01.016","article-title":"Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease","volume":"46","author":"Jia","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/hmg\/ddg002","article-title":"Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein","volume":"12","author":"Jiang","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib62","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.nbd.2006.04.011","article-title":"Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin","volume":"23","author":"Jiang","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib63","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1093\/nar\/gkq223","article-title":"Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosine and 5-hydroxymethylcytosine","volume":"38","author":"Jin","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib64","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1126\/science.1139517","article-title":"CREB-binding protein modulates repeat instability in a Drosophila model for polyQ disease","volume":"315","author":"Jung","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib65","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/978-1-4614-0332-6_11","article-title":"Long noncoding RNA and epigenomics","volume":"722","author":"Kanduri","year":"2011","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib66","doi-asserted-by":"crossref","first-page":"11404","DOI":"10.1073\/pnas.96.20.11404","article-title":"Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells","volume":"96","author":"Kazantsev","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib67","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.mcn.2005.04.005","article-title":"Evidence for sequestration of polyglutamine inclusions by Drosophila myeloid leukemia factor","volume":"29","author":"Kim","year":"2005","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib68","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1523\/JNEUROSCI.5667-07.2008","article-title":"Altered histone monoubiquitylation mediated by mutant huntingtin induces transcriptional dysregulation","volume":"28","author":"Kim","year":"2008","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib69","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/hmg\/11.19.2279","article-title":"Modulation of polyglutamine-induced cell death by genes identified by expression profiling","volume":"11","author":"Kita","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib70","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/NEN.0b013e3181d6c436","article-title":"Partial depletion of CREB-binding protein reduces life expectancy in a mouse model of Huntington disease","volume":"69","author":"Klevytska","year":"2010","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib71","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/cdd.2011.196","article-title":"ATRX induction by mutant huntingtin via Cdx2 modulates heterochromatin condensation and pathology in Huntington's disease","volume":"19","author":"Lee","year":"2012","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib72","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00401-013-1103-z","article-title":"Epigenetic regulation of cholinergic receptor M1 (CHRM1) by histone H3K9me3 impairs Ca(2+) signaling in Huntington's disease","volume":"125","author":"Lee","year":"2013","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib73","first-page":"870726","article-title":"Distribution of 5-hydroxymethylcytosine in different human tissues","volume":"2011","author":"Li","year":"2011","journal-title":"J.\u00a0Nucleic Acids"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib74","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1128\/MCB.22.5.1277-1287.2002","article-title":"Interaction of Huntington disease protein with transcriptional activator Sp1","volume":"22","author":"Li","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib75","doi-asserted-by":"crossref","first-page":"e24620","DOI":"10.1371\/journal.pone.0024620","article-title":"d-beta-hydroxybutyrate is protective in mouse models of Huntington's disease","volume":"6","author":"Lim","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib76","doi-asserted-by":"crossref","first-page":"1237905","DOI":"10.1126\/science.1237905","article-title":"Global epigenomic reconfiguration during mammalian brain development","volume":"341","author":"Lister","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib77","doi-asserted-by":"crossref","first-page":"8072","DOI":"10.1093\/nar\/gkt590","article-title":"Genomic targets, and histone acetylation and gene expression profiling of neural HDAC inhibition","volume":"41","author":"Lopez-Atalaya","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib78","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.celrep.2012.07.006","article-title":"Proteomic analysis of lysine acetylation sites in rat tissues reveals organ specificity and subcellular patterns","volume":"2","author":"Lundby","year":"2012","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib79","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.1074\/jbc.M110.146860","article-title":"Neuroprotection by histone deacetylase-7 (HDAC7) occurs by inhibition of c-jun expression through a deacetylase-independent mechanism","volume":"286","author":"Ma","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib80","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/hmg\/ddr148","article-title":"Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter","volume":"20","author":"Martin","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib81","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/hmg\/9.14.2197","article-title":"CREB-binding protein sequestration by expanded polyglutamine","volume":"9","author":"McCampbell","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib82","doi-asserted-by":"crossref","first-page":"15179","DOI":"10.1073\/pnas.261400698","article-title":"Histone deacetylase inhibitors reduce polyglutamine toxicity","volume":"98","author":"McCampbell","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib83","doi-asserted-by":"crossref","first-page":"e41423","DOI":"10.1371\/journal.pone.0041423","article-title":"Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington's disease","volume":"7","author":"McFarland","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib84","doi-asserted-by":"crossref","first-page":"e27746","DOI":"10.1371\/journal.pone.0027746","article-title":"SAHA decreases HDAC 2 and 4 levels in\u00a0vivo and improves molecular phenotypes in the R6\/2 mouse model of Huntington's disease","volume":"6","author":"Mielcarek","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib85","doi-asserted-by":"crossref","first-page":"e31080","DOI":"10.1371\/journal.pone.0031080","article-title":"Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease","volume":"7","author":"Moumne","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib86","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2144\/000113403","article-title":"Enzymatic approaches and bisulfite sequencing cannot distinguish between 5-methylcytosine and 5-hydroxymethylcytosine in DNA","volume":"48","author":"Nestor","year":"2010","journal-title":"Biotechniques"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib87","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1073\/pnas.1221292110","article-title":"Extensive changes in DNA methylation are associated with expression of mutant huntingtin","volume":"110","author":"Ng","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib88","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1126\/science.1056784","article-title":"Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity","volume":"291","author":"Nucifora","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib89","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1523\/JNEUROSCI.3493-03.2004","article-title":"CRE-mediated transcription is increased in Huntington's disease transgenic mice","volume":"24","author":"Obrietan","year":"2004","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib90","doi-asserted-by":"crossref","first-page":"11174","DOI":"10.1523\/JNEUROSCI.3004-06.2006","article-title":"Mitochondrial-dependent Ca2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors","volume":"26","author":"Oliveira","year":"2006","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib91","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1093\/hmg\/ddn273","article-title":"Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease","volume":"17","author":"Pallos","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib92","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1101\/lm.029363.112","article-title":"Histone H3 lysine methylation in cognition and intellectual disability disorders","volume":"20","author":"Parkel","year":"2013","journal-title":"Learn Mem."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib93","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2174\/1389557511313050001","article-title":"Anthracyclines still prove effective in anticancer therapy","volume":"13","author":"Piekarski","year":"2013","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib94","doi-asserted-by":"crossref","first-page":"16672","DOI":"10.1074\/jbc.M511648200","article-title":"Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective","volume":"281","author":"Qiu","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib95","doi-asserted-by":"crossref","DOI":"10.1371\/currents.RRN1172","article-title":"Evaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6\/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model","volume":"2","author":"Quinti","year":"2010","journal-title":"PLoS Curr."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib96","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.gde.2012.02.013","article-title":"Combinatorial complexity in chromatin structure and function: revisiting the histone code","volume":"22","author":"Rando","year":"2012","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib97","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1096\/fj.07-9814","article-title":"Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death","volume":"22","author":"Roze","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib98","doi-asserted-by":"crossref","first-page":"19176","DOI":"10.1073\/pnas.0606373103","article-title":"ESET\/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease","volume":"103","author":"Ryu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib99","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1111\/j.1460-9568.2006.04871.x","article-title":"Huntingtin inclusions do not down-regulate specific genes in the R6\/2 Huntington's disease mouse","volume":"23","author":"Sadri-Vakili","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib100","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/hmg\/ddm078","article-title":"Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models","volume":"16","author":"Sadri-Vakili","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib101","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.nbd.2011.07.001","article-title":"What have we learned from gene expression profiles in Huntington's disease?","volume":"45","author":"Seredenina","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib102","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/hmg\/11.17.1953","article-title":"Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses","volume":"11","author":"Sipione","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib103","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/j.1460-9568.2006.04641.x","article-title":"Histone modifications in kainate-induced status epilepticus","volume":"23","author":"Sng","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib104","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nbt.1732","article-title":"Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine","volume":"29","author":"Song","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib105","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/hmg\/ddm064","article-title":"Modulation of nucleosome dynamics in Huntington's disease","volume":"16","author":"Stack","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib106","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1073\/pnas.100110097","article-title":"The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription","volume":"97","author":"Steffan","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib107","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35099568","article-title":"Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila","volume":"413","author":"Steffan","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib108","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.5858\/2007-131-1686-UOTTFT","article-title":"Utility of tissue-specific transcription factors thyroid transcription factor 1 and Cdx2 in determining the primary site of metastatic adenocarcinomas to the brain","volume":"131","author":"Strickland-Marmol","year":"2007","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib109","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.neuroscience.2004.10.037","article-title":"Neuronal intranuclear inclusions and neuropil aggregates in HdhCAG(150) knockin mice","volume":"131","author":"Tallaksen-Greene","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib110","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1101\/gad.1087503","article-title":"Aberrant histone acetylation, altered transcription, and retinal degeneration in a Drosophila model of polyglutamine disease are rescued by CREB-binding protein","volume":"17","author":"Taylor","year":"2003","journal-title":"Genes Dev."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib111","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/ng0494-409","article-title":"Somatic and gonadal mosaicism of the Huntington disease gene CAG repeat in brain and sperm","volume":"6","author":"Telenius","year":"1994","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib112","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1073\/pnas.0804249105","article-title":"The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice","volume":"105","author":"Thomas","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib113","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ab.2013.01.035","article-title":"A\u00a0novel method for detecting 7-methyl guanine reveals aberrant methylation levels in Huntington disease","volume":"436","author":"Thomas","year":"2013","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib114","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1083\/jcb.200909067","article-title":"IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome","volume":"187","author":"Thompson","year":"2009","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib115","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1523\/JNEUROSCI.0589-04.2004","article-title":"Histone modifications at gene promoter regions in rat hippocampus after acute and chronic electroconvulsive seizures","volume":"24","author":"Tsankova","year":"2004","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib116","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/hipo.20888","article-title":"Hippocampal gene profiling: towards a systems biology of the hippocampus","volume":"22","author":"Valor","year":"2012","journal-title":"Hippocampus"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib117","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1523\/JNEUROSCI.4737-10.2011","article-title":"Ablation of CBP in forebrain principal neurons causes modest memory and transcriptional defects and a dramatic reduction of histone acetylation but does not affect cell viability","volume":"31","author":"Valor","year":"2011","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib118","doi-asserted-by":"crossref","first-page":"10471","DOI":"10.1523\/JNEUROSCI.0670-13.2013","article-title":"Genomic landscape of transcriptional and epigenetic dysregulation in early onset polyglutamine disease","volume":"33","author":"Valor","year":"2013","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib119","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.2174\/13816128113199990382","article-title":"Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders","volume":"19","author":"Valor","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib120","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1101\/gr.147942.112","article-title":"Dynamic DNA methylation across diverse human cell lines and tissues","volume":"23","author":"Varley","year":"2013","journal-title":"Genome Res."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib121","doi-asserted-by":"crossref","first-page":"E3027","DOI":"10.1073\/pnas.1311323110","article-title":"Targeting H3K4 trimethylation in Huntington disease","volume":"110","author":"Vashishtha","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib122","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12017-013-8219-0","article-title":"Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease","volume":"15","author":"Villar-Menendez","year":"2013","journal-title":"Neuromolecular Med."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib123","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ng.154","article-title":"Combinatorial patterns of histone acetylations and methylations in the human genome","volume":"40","author":"Wang","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib124","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1093\/hmg\/ddt214","article-title":"Genome-wide loss of 5-hmC is a novel epigenetic feature of Huntington's disease","volume":"22","author":"Wang","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib125","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.cell.2011.12.035","article-title":"Base-resolution analyses of sequence and parent-of-origin dependent DNA methylation in the mouse genome","volume":"148","author":"Xie","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib126","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0006-291X(03)00115-3","article-title":"Histone H3 is aberrantly phosphorylated in glutamine-repeat diseases","volume":"302","author":"Yazawa","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib127","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.brainres.2013.02.012","article-title":"Histone deacetylase class II and acetylated core histone immunohistochemistry in human brains with Huntington's disease","volume":"1504","author":"Yeh","year":"2013","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib128","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/hmg\/11.8.905","article-title":"Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice","volume":"11","author":"Yu","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib129","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pbb.2009.08.001","article-title":"Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease","volume":"94","author":"Zadori","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2013.10.025_bib130","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/hipo.20658","article-title":"Wheel running and environmental enrichment differentially modify exon-specific BDNF expression in the hippocampus of wild-type and pre-motor symptomatic male and female Huntington's disease mice","volume":"20","author":"Zajac","year":"2010","journal-title":"Hippocampus"},{"key":"10.1016\/j.neuropharm.2013.10.025_bib131","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular mechanisms and potential therapeutical targets in Huntington's disease","volume":"90","author":"Zuccato","year":"2010","journal-title":"Physiol. Rev."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813005017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813005017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T05:11:38Z","timestamp":1716095498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390813005017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":131,"alternative-id":["S0028390813005017"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.10.025","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What's wrong with epigenetics in Huntington's disease?","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.10.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}